176 related articles for article (PubMed ID: 29458117)
21. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
Pandi-Perumal SR; Moscovitch A; Srinivasan V; Spence DW; Cardinali DP; Brown GM
Prog Neurobiol; 2009 Aug; 88(4):264-71. PubMed ID: 19454302
[TBL] [Abstract][Full Text] [Related]
22. L-3,4-Dihydroxyphenylalanine Recovers Circadian Rhythm Disturbances in the Rat Models of Parkinson's Disease by Regulating the D1R-ERK1/2-mTOR Pathway.
Yang S; Wan Y; Wu N; Song L; Liu Z; Zhao J; Liu Y; Liu Z; Gan J
Front Aging Neurosci; 2021; 13():719885. PubMed ID: 34489685
[No Abstract] [Full Text] [Related]
23. Investigation of non-invasive focused ultrasound efficacy on depressive-like behavior in hemiparkinsonian rats.
Herlihy RA; Alicandri F; Berger H; Rehman H; Kao Y; Akhtar K; Dybas E; Mahoney-Rafferty E; Von Stein K; Kirby R; Tawfik A; Skumurski R; Feustel PJ; Molho ES; Shin DS
Exp Brain Res; 2024 Feb; 242(2):321-336. PubMed ID: 38059986
[TBL] [Abstract][Full Text] [Related]
24. Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrine.
Szot P; Franklin A; Miguelez C; Wang Y; Vidaurrazaga I; Ugedo L; Sikkema C; Wilkinson CW; Raskind MA
Neuropharmacology; 2016 Feb; 101():76-86. PubMed ID: 26362360
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
26. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Cronin A; Grealy M
Neuroscience; 2017 Dec; 367():34-46. PubMed ID: 29079063
[TBL] [Abstract][Full Text] [Related]
28. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety.
Rainer Q; Xia L; Guilloux JP; Gabriel C; Mocaër E; Hen R; Enhamre E; Gardier AM; David DJ
Int J Neuropsychopharmacol; 2012 Apr; 15(3):321-35. PubMed ID: 21473810
[TBL] [Abstract][Full Text] [Related]
29. The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease.
Santiago RM; Tonin FS; Barbiero J; Zaminelli T; Boschen SL; Andreatini R; Da Cunha C; Lima MM; Vital MA
Neuroscience; 2015 Aug; 300():246-53. PubMed ID: 25999296
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease.
Kim J; Park I; Jang S; Choi M; Kim D; Sun W; Choe Y; Choi JW; Moon C; Park SH; Choe HK; Kim K
Neurotherapeutics; 2022 Mar; 19(2):592-607. PubMed ID: 35322351
[TBL] [Abstract][Full Text] [Related]
31. Behavior and oxidative stress parameters in rats subjected to the animal's models induced by chronic mild stress and 6-hydroxydopamine.
Tuon T; Meirelles SS; de Moura AB; Rosa T; Borba LA; Botelho MEM; Abelaira HM; de Mathia GB; Danielski LG; Fileti ME; Petronilho F; Ignácio ZM; Quevedo J; Réus GZ
Behav Brain Res; 2021 May; 406():113226. PubMed ID: 33684423
[TBL] [Abstract][Full Text] [Related]
32. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
[TBL] [Abstract][Full Text] [Related]
33. Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies.
Ahmad M; Yousuf S; Khan MB; Hoda MN; Ahmad AS; Ansari MA; Ishrat T; Agrawal AK; Islam F
Pharmacol Biochem Behav; 2006 Jan; 83(1):150-60. PubMed ID: 16500697
[TBL] [Abstract][Full Text] [Related]
34. Depressive-like neurochemical and behavioral markers of Parkinson's disease after 6-OHDA administered unilaterally to the rat medial forebrain bundle.
Kamińska K; Lenda T; Konieczny J; Czarnecka A; Lorenc-Koci E
Pharmacol Rep; 2017 Oct; 69(5):985-994. PubMed ID: 28843848
[TBL] [Abstract][Full Text] [Related]
35. The preclinical discovery and development of agomelatine for the treatment of depression.
Konstantakopoulos G; Dimitrakopoulos S; Michalopoulou PG
Expert Opin Drug Discov; 2020 Oct; 15(10):1121-1132. PubMed ID: 32568567
[TBL] [Abstract][Full Text] [Related]
36. Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.
Vecchia DD; Kanazawa LKS; Wendler E; Hocayen PAS; Vital MABF; Takahashi RN; Da Cunha C; Miyoshi E; Andreatini R
Brain Res Bull; 2021 Mar; 168():63-73. PubMed ID: 33359641
[TBL] [Abstract][Full Text] [Related]
37. Effects of 6-hydroxydopamine lesioning of the medial prefrontal cortex on social interactions in adolescent and adult rats.
Li CR; Huang GB; Sui ZY; Han EH; Chung YC
Brain Res; 2010 Jul; 1346():183-9. PubMed ID: 20513371
[TBL] [Abstract][Full Text] [Related]
38. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
39. Chronic agomelatine and fluoxetine induce antidepressant-like effects in H/Rouen mice, a genetic mouse model of depression.
El Yacoubi M; Dubois M; Gabriel C; Mocaër E; Vaugeois JM
Pharmacol Biochem Behav; 2011 Dec; 100(2):284-8. PubMed ID: 21843546
[TBL] [Abstract][Full Text] [Related]
40. Involvement of BDNF/TrkB signaling in the effect of diphenyl diselenide on motor function in a Parkinson's disease rat model.
Sampaio TB; Pinton S; da Rocha JT; Gai BM; Nogueira CW
Eur J Pharmacol; 2017 Jan; 795():28-35. PubMed ID: 27915043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
